Stock listing
NASDAQ:DRTS Alpha Tau Medical Ltd Stock
Home listing (NASDAQ) of Alpha Tau Medical Ltd
Follow Alpha Tau Medical Ltd into a list and get an email when it puts out news.
Share price · NASDAQ:DRTS
$11.76 USD -0.25 (-2.1%)
Close on Nov 20, 2026
- Day range
- $11.32 – $12.19 USDNov 20, 2026
- Volume
- 626,868 sharesNov 20, 2026
- Market cap
- $1.09B USDAt the close on Nov 20, 2026 · price × 92.48M shares outstanding
- 52-week range
- $3.43 – $15.79 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $8.02M USDMedian day 467,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DRTS · Home | $11.76 USD | -0.255 (-2.1%) | 626,868 | $11.47 | $12.19 | $11.32 | $12.01 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DRTS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $11.76 | -0.255 | -2.1% | $11.47 | $12.19 | $11.32 | 626,868 | |
| $12.01 | -0.08 | -0.7% | $12.05 | $12.22 | $11.82 | 640,029 | |
| $12.09 | +0.12 | +1.0% | $12.00 | $12.30 | $11.67 | 1,077,732 | |
| $11.97 | -1.41 | -10.5% | $14.40 | $14.41 | $11.81 | 2,286,815 | |
| $13.38 | +0.02 | +0.1% | $13.45 | $13.49 | $12.98 | 403,519 | |
| $13.36 | -0.66 | -4.7% | $13.92 | $13.92 | $13.15 | 611,186 | |
| $14.02 | +0.32 | +2.3% | $14.00 | $14.59 | $14.00 | 833,549 | |
| $13.70 | -0.41 | -2.9% | $13.90 | $14.17 | $13.60 | 426,928 | |
| $14.11 | +0.39 | +2.8% | $13.99 | $14.43 | $13.80 | 494,895 | |
| $13.72 | +0.42 | +3.2% | $13.51 | $13.98 | $13.16 | 417,324 | |
| $13.30 | -0.73 | -5.2% | $13.93 | $13.98 | $12.99 | 671,648 | |
| $14.03 | +0.49 | +3.6% | $13.85 | $14.20 | $13.59 | 685,874 | |
| $13.54 | +0.71 | +5.5% | $13.07 | $13.63 | $13.07 | 662,011 | |
| $12.83 | -0.23 | -1.8% | $13.22 | $13.23 | $12.67 | 436,732 | |
| $13.06 | -0.17 | -1.3% | $12.85 | $13.15 | $12.74 | 475,222 | |
| $13.23 | -0.12 | -0.9% | $13.31 | $13.55 | $13.06 | 282,833 | |
| $13.35 | -0.16 | -1.2% | $13.51 | $13.61 | $13.27 | 401,163 | |
| $13.51 | +0.62 | +4.8% | $12.99 | $13.66 | $12.71 | 341,843 | |
| $12.89 | -0.27 | -2.1% | $13.18 | $13.56 | $12.77 | 379,003 | |
| $13.16 | +0.26 | +2.0% | $12.75 | $13.25 | $12.70 | 324,175 | |
| $12.90 | -0.58 | -4.3% | $13.25 | $13.46 | $12.71 | 447,711 | |
| $13.48 | +0.39 | +3.0% | $13.47 | $13.85 | $13.30 | 500,316 | |
| $13.09 | +0.47 | +3.7% | $12.61 | $13.38 | $12.50 | 833,535 | |
| $12.62 | +0.33 | +2.7% | $12.56 | $12.81 | $12.42 | 688,391 | |
| $12.29 | -0.87 | -6.6% | $13.24 | $13.30 | $11.99 | 778,700 | |
| $13.16 | -0.34 | -2.5% | $13.14 | $13.47 | $13.02 | 620,300 | |
| $13.50 | -0.24 | -1.7% | $13.48 | $13.79 | $13.34 | 422,000 | |
| $13.74 | -0.52 | -3.6% | $14.11 | $14.25 | $13.65 | 484,600 | |
| $14.26 | -0.15 | -1.0% | $14.42 | $14.44 | $14.11 | 281,500 | |
| $14.41 | +0.41 | +2.9% | $14.00 | $14.50 | $13.98 | 368,000 | |
| $14.00 | -0.25 | -1.8% | $14.17 | $14.30 | $13.56 | 595,200 | |
| $14.25 | -0.23 | -1.6% | $14.27 | $14.44 | $14.10 | 466,300 | |
| $14.48 | -0.41 | -2.8% | $14.98 | $15.02 | $14.40 | 427,400 | |
| $14.89 | +0.12 | +0.8% | $14.85 | $15.04 | $14.68 | 342,400 | |
| $14.77 | +0.26 | +1.8% | $14.73 | $14.91 | $14.64 | 307,100 | |
| $14.51 | -0.40 | -2.7% | $14.74 | $14.97 | $14.32 | 379,900 | |
| $14.91 | -0.28 | -1.8% | $15.14 | $15.34 | $14.88 | 368,900 | |
| $15.19 | +0.15 | +1.0% | $15.00 | $15.30 | $14.77 | 513,900 | |
| $15.04 | +0.50 | +3.4% | $14.54 | $15.20 | $14.39 | 397,400 | |
| $14.54 | -0.23 | -1.6% | $14.90 | $14.92 | $14.39 | 435,400 | |
| $14.77 | +0.25 | +1.7% | $14.50 | $14.80 | $14.31 | 467,000 | |
| $14.52 | -0.62 | -4.1% | $15.09 | $15.25 | $14.31 | 727,000 | |
| $15.14 | -0.36 | -2.3% | $15.38 | $15.45 | $15.05 | 360,400 | |
| $15.50 | +0.26 | +1.7% | $15.48 | $15.59 | $15.10 | 411,400 | |
| $15.24 | -0.25 | -1.6% | $15.60 | $15.63 | $15.10 | 624,200 | |
| $15.49 | +0.45 | +3.0% | $15.15 | $15.79 | $15.01 | 858,700 | |
| $15.04 | +0.17 | +1.1% | $14.88 | $15.20 | $14.73 | 671,000 | |
| $14.87 | +0.47 | +3.3% | $14.30 | $15.00 | $14.20 | 411,600 | |
| $14.40 | -0.03 | -0.2% | $14.11 | $14.84 | $14.11 | 388,000 | |
| $14.43 | -0.01 | -0.1% | $14.49 | $14.62 | $14.01 | 410,400 | |
| $14.44 | +0.17 | +1.2% | $14.04 | $14.81 | $13.80 | 457,200 | |
| $14.27 | -0.57 | -3.8% | $14.70 | $14.84 | $14.27 | 412,000 | |
| $14.84 | -0.19 | -1.3% | $15.03 | $15.08 | $14.47 | 561,500 | |
| $15.03 | +0.41 | +2.8% | $14.69 | $15.17 | $14.43 | 749,300 | |
| $14.62 | +0.29 | +2.0% | $15.00 | $15.07 | $14.32 | 629,700 | |
| $14.33 | +0.37 | +2.7% | $14.25 | $14.65 | $13.88 | 372,500 | |
| $13.96 | -0.15 | -1.1% | $13.96 | $14.40 | $13.65 | 464,800 | |
| $14.11 | -0.53 | -3.6% | $14.69 | $15.00 | $14.05 | 3,115,700 | |
| $14.64 | -0.17 | -1.1% | $14.76 | $14.90 | $14.45 | 475,300 | |
| $14.81 | -0.15 | -1.0% | $14.83 | $15.10 | $14.75 | 474,500 | |
| $14.96 | +0.26 | +1.8% | $14.70 | $15.00 | $14.58 | 432,500 | |
| $14.70 | 0.00 | 0.0% | $14.74 | $14.98 | $14.50 | 495,000 | |
| $14.70 | -0.22 | -1.5% | $14.93 | $15.00 | $14.57 | 483,400 | |
| $14.92 | +0.56 | +3.9% | $14.57 | $15.02 | $14.40 | 626,200 | |
| $14.36 | -0.11 | -0.8% | $14.47 | $14.60 | $14.20 | 349,200 |
- Ticker
- NASDAQ:DRTS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · Nov 16, 2026
Corporate Update (November 2026)
Corporate update · 28 slides
Latest news
Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 19, 2026
Closed $11.76 (-2.1%) on Nov 20, 2026
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
Nov 12, 2026
Closed $13.36 (-4.7%) on Nov 12, 2026
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
Oct 22, 2026
Closed $12.90 (-4.3%) on Oct 22, 2026
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
Oct 19, 2026
Closed $12.62 (+2.7%) on Oct 19, 2026
Alpha Tau to Participate in October Investor Conferences
Oct 5, 2026
Closed $14.89 (+0.8%) on Oct 5, 2026
Alpha Tau to Participate in September Investor Conferences
Sep 2, 2026
Closed $14.33 (+2.7%) on Sep 2, 2026
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
Aug 31, 2026
Closed $14.11 (-3.6%) on Aug 31, 2026
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 10, 2026
Closed $14.27 (+4.9%) on Aug 11, 2026
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
Jul 21, 2026
Closed $13.32 (-1.1%) on Jul 21, 2026
Alpha Tau Medical Ltd on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 35 in the last 12 months · 50 in all · newest Nov 19, 2026 · oldest 2025
- Decks
- 9 decks · latest Nov 16, 2026
Where Alpha Tau Medical Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DRTS · Home listing · This page | NASDAQ | United States | USD |
| TASE:DRTS | TASE | Israel | ILA |
| BOATS:DRTS | BOATS | United States | USD |
Valuation
Price/book 55.3× against a median of 2.6×: 10th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.00B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 55.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.8×
- Beta vs S&P 500
- 1.89
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alpha Tau Medical Ltd · NASDAQ:DRTS | US$1.09B | US$1.00B | n/a | n/a | n/a | 55.3× | n/a | 0.8× | 1.89 |
| Structure Therapeutics, Inc. · NASDAQ:GPCR | US$1.15B | −US$82.92M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.38 |
| COMPASS Pathways Plc · NASDAQ:CMPS | US$1.14B | US$747.8M | n/a | n/a | n/a | 8.0× | n/a | 0.4× | 1.65 |
| Ascentage Pharma Group International · HKEX:6855 | US$1.11B | US$1.14B | n/a | 13.7× | n/a | 13.4× | −216.5% | 3.8× | n/a |
| Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321 | US$1.10B | US$1.10B | 102× | 6.8× | n/a | 2.9× | 6.6% | 0.5× | n/a |
| Pharma Mar SA · BME:PHM | US$1.10B | US$978.5M | 14.6× | 3.8× | 16.6× | 4.2× | 28.8% | 0.3× | n/a |
| Kardigan, Inc. · NASDAQ:KARD | US$1.08B | US$621.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| PYC Therapeutics Limited · ASX:PYC | US$1.07B | US$775.8M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Jade Biosciences, Inc. · NASDAQ:JBIO | US$1.06B | US$583.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.14 |
| MedinCell SA · EURONEXT:MEDCL | US$1.05B | US$1.02B | n/a | 38.4× | n/a | 313× | −128.9% | 18.7× | n/a |
| Nektar Therapeutics · NASDAQ:NKTR | US$1.03B | US$492.8M | n/a | 9.4× | n/a | 1.2× | −339.7% | 0.1× | 1.28 |
| Median of the others | US$1.09B | US$761.8M | 58.5× | 9.4× | 16.6× | 2.6× | −128.9% | 0.2× | 1.33 |
Forecasts
3 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.24 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Uzi Sofer | CEO & Chairman |
| Raphi Levy | Chief Financial Officer |
| Amnon Gat | Chief Operations Officer |
| Robert Den | Chief Medical Officer |
| Ronen Segal | Chief Technology Officer |
| Yona Keisari | Chief Scientific Officer & Co-Inventor |
Board
| Director | Role |
|---|---|
| Uzi Sofer | CEO & Chairman |
| Alan Adler | Director |
| David M. Milch | Director |
| Maya Netser | Director |
| Michael Avruch | Director |
| Morry Blumenfeld | Director |
| Nadav Kidron | Director |
| Ruth Alon | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 19, 2026 · After close | −2.1% |
| Q2 2026 | Aug 10, 2026 · After close | +4.9% |
| Q1 2026 | May 18, 2026 · After close | +6.5% |
| Q4 2025 | Mar 5, 2026 | −8.7% |
| Q3 2025 | Nov 20, 2025 · After close | +10.1% |
| Q2 2025 | Aug 11, 2025 · After close | −8.7% |
| Q1 2025 | May 19, 2025 · After close | +5.2% |
| Q4 2024 | Mar 12, 2025 | +0.8% |
| Q3 2024 | Nov 19, 2024 · After close | −0.2% |
| Q2 2024 | Aug 14, 2024 · After close | +6.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 20, 2024 · After close | 0.0% |
| Q4 2023 | Mar 7, 2024 · After close | −0.7% |
| Q3 2023 | Nov 16, 2023 · After close | +4.1% |
| Q2 2023 | Aug 28, 2023 · After close | +3.1% |
| Q1 2023 | May 23, 2023 · After close | +3.5% |
| Q4 2022 | Mar 9, 2023 · After close | −1.5% |
| Q3 2022 | Nov 22, 2022 · After close | +3.2% |
| Q2 2022 | Aug 25, 2022 · After close | +1.7% |
| Q1 2022 | May 26, 2022 · After close | +4.4% |
| Q4 2021 | Mar 28, 2022 · Before open | +6.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 28 slides | Nov 16, 2026 |
| Investor Presentation (August 2026) | Investor deck | 41 slides | Aug 22, 2026 |
| Technical Presentation (May 2026) | Technical | 52 slides | May 2026 |
| Investor Presentation (March 2026) | Investor deck | 37 slides | Mar 9, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 34 slides | Jan 5, 2026 |
| Investor Day (January 2025) | Investor day | 84 slides | January 2025 |
| Investor Presentation (July 2022) | Investor deck | 68 slides | Jul 18, 2022 |
| SPAC Merger (January 2022) | SPAC merger | 35 slides | Jan 12, 2022 |
| SPAC Merger (July 2021) | SPAC merger | 40 slides | Jul 8, 2021 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of ordinary shares Closed: US$36.9M raised · US$2.612 a share Buyers: Oramed Pharmaceuticals Inc. (affiliate) (14,110,121 ordinary shares at $2.612 per share) Use of proceeds: General corporate purposes, including R&D for product candidates, expanding manufacturing capabilities and potential commercialization | Apr 28, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.23M | 1.10M | 1.07M | 979.0K | 776.0K | 86.0K | |
| Gross profit | -1.23M | -1.10M | -1.07M | -979.0K | -776.0K | -86.0K | |
| Research and development | 32.1M | 27.0M | 26.4M | 20.9M | 11.4M | 7.54M | 6.64M |
| Selling, general and administrative | 8.36M | 6.67M | 7.33M | 10.3M | 1.86M | 1.41M | 977.0K |
| Operating income | -42.3M | -36.0M | -35.7M | -32.1M | -13.8M | -9.24M | 8.01M |
| Depreciation and amortization | 1.23M | 1.10M | 1.07M | 979.0K | 776.0K | 86.0K | 66.0K |
| EBITDA | -41.1M | -34.9M | -34.6M | -31.2M | -13.0M | -9.16M | 8.08M |
| Interest expense | 347.0K | 303.0K | 75.0K | 1.77M | 12.7M | 217.0K | 1.28M |
| Income before tax | -42.5M | -31.7M | -29.1M | -33.7M | -27.3M | -8.72M | 8.32M |
| Income tax | 121.0K | 6.00K | 16.0K | 20.0K | 7.00K | 158.0K | -146.0K |
| Net income | -42.6M | -31.8M | -29.2M | -33.8M | -27.3M | -8.88M | -8.37M |
| Earnings per share, basic | -0.53 | -0.45 | -0.42 | -0.53 | -0.67 | -0.22 | -0.25 |
| Earnings per share, diluted | -0.53 | -0.45 | -0.42 | -0.53 | -0.67 | -0.22 | -0.25 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 12.2M | 13.7M | 12.7M | 5.84M | 23.2M | 15.6M | 1.84M |
| Short-term investments | 60.9M | 45.9M | 69.1M | 98.7M | 8.08M | 30.4M | 26.3M |
| Receivables | 336.0K | 332.0K | 344.0K | 32.0K | 480.0K | 477.0K | 141.0K |
| Inventory | -19.0K | -1.06M | -8.17M | -29.8M | 1.13M | ||
| Current assets | 78.3M | 64.2M | 85.8M | 106.5M | 32.6M | 47.5M | 29.8M |
| Property, plant and equipment | 19.7M | 13.9M | 12.8M | 7.47M | 7.55M | 5.39M | 1.71M |
| Total assets | 105.7M | 86.2M | 107.4M | 120.1M | 42.2M | 53.0M | 31.6M |
| Accounts payable | 3.87M | 3.53M | 2.57M | 1.42M | 1.20M | 964.0K | 893.0K |
| Current liabilities | 10.5M | 8.68M | 7.10M | 4.34M | 4.41M | 2.09M | 1.35M |
| Long-term debt | 6.35M | 5.56M | 5.61M | ||||
| Total debt | 13.7M | 12.5M | 13.3M | 5.19M | 54.0M | 54.0M | |
| Total liabilities | 28.6M | 23.5M | 22.9M | 14.5M | 23.0M | 7.45M | 31.8M |
| Shareholders' equity | 77.1M | 62.7M | 84.5M | 105.7M | -34.8M | -8.43M | -193.0K |
| Shares outstanding | 88.0M | 70.4M | 69.7M | 69.1M | 40.5M | 40.4M | 69.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -26.7M | -19.8M | -18.0M | -23.9M | -11.8M | -7.25M | -6.91M |
| Capital spending | -6.08M | -2.24M | -6.40M | -904.0K | -2.93M | -3.77M | -1.29M |
| Free cash flow | -32.8M | -22.0M | -24.4M | -24.8M | -14.7M | -11.0M | -8.20M |
| Cash from investing | -20.6M | 20.8M | 18.7M | -89.9M | 19.3M | -7.82M | -10.2M |
| Cash from financing | 45.8M | 25.0K | 5.30M | 96.9M | 111.0K | 29.3M | 5.32M |
| Change in cash | -1.52M | 1.07M | 5.97M | -17.2M | 7.68M | 14.3M | -11.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 29, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 22, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 31, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
Show 200 filings
This page holds 200 of 243 filings. Open Filings
Cap table
Built by 6ix from Alpha Tau Medical Ltd’s releases · as of Sep 30, 2026
- Common shares
- 92,478,154
- Fully diluted
- 92,478,154
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 92,478,154 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 92,478,154 |
| Sep 30, 2026 | 93,084,841 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Nadav Kidron Other companies: Nano Dimension Ltd (Director · Since at least Aug 16, 2026); Lifeward Ltd. (Director · Since at least Mar 25, 2026); Oramed Pharmaceuticals Inc. (President and CEO, Director · Since at least Feb 3, 2006) | Director · Since at least May 12, 2025 |
| Alan Adler | Director · Since at least Nov 5, 2026 |
| Amnon Gat | Chief Operations Officer · Since at least Nov 5, 2026 |
| David M. Milch | Director · Since at least Mar 18, 2026 |
| Maya Netser | Director · Since at least Mar 18, 2026 |
| Michael Avruch | Director · Since at least Nov 5, 2026 |
| Morry Blumenfeld | Director · Since at least Mar 18, 2026 |
| Raphi Levy | Chief Financial Officer · Since at least Aug 25, 2026 |
| Robert Den | Chief Medical Officer · Since at least Oct 19, 2026 |
| Ronen Segal | Chief Technology Officer · Since at least Nov 5, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Ruth Alon | Director · Since at least Nov 5, 2026 |
| Uzi Sofer | CEO & Chairman · Since at least Mar 18, 2026 |
| Yona Keisari | Chief Scientific Officer & Co-Inventor · Since at least Oct 22, 2026 |
Log in to ask 6ix AI your own questions about Alpha Tau Medical Ltd.